Skip to main content

Oncology Central is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • News
  • Events coverage
  • Features
    • Opinion
    • Journal articles
    • Events calendar
    • Spotlights
    • In Focus

    Follow us on social media

  • Our Journals
  • Topic
    • Prevention, detection and screening
      • Biomarkers
      • Diagnostics
      • Epidemiology
      • Genetics & genomics
      • Prevention & screening
    • Bench to bedside
      • Cancer biology
      • Clinical trials
      • Drug approvals
      • Drug development
      • Emerging technologies
      • Industry & business
      • Preclinical research
    • Treatments
      • Chemotherapy
      • Immuno-oncology
      • Personalized & precision medicine
      • Radiology
      • Surgery
      • Targeted therapies
    • Supportive oncology
      • Palliative care
      • Patient perspectives
      • Quality of life
      • Survivorship
      • Virtual healthcare

    Follow us on social media

  • Disease specialty
    • Breast
    • Colorectal
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Gynecologic
    • Head & neck
    • Hematologic
    • Hepatic
    • Lung
    • Neurologic
    • Pancreatic
    • Prostate
    • Rare tumors
    • Renal
    • Skin

    Follow us on social media

  • Multimedia
    • Videos
    • Podcasts
    • Infographics
    • Webinars
    • Downloadable eBooks

    Follow us on social media

  • Register
[COFFEE CHAT] The emotional and psychological impact of hepatocellular carcinoma on patients, families and caregivers WATCH NOW

In Focus: breast cancer

The roll out of more effective and affordable screening programes alongside advancements in treatment options have resulted in declining death rates over the last few decades. Despite this, breast cancer remains the most common type of cancer in woman globally with approximately 1.5 million new cases diagnosed each year.

Articles

New method for predicting breast cancer risk could be a game changer
NCRI 2018: Women who are ‘larks’ have a lower risk of developing breast cancer, study suggests
Triple-negative breast cancer risk genes discovered
IMpassion130: first positive Phase III immunotherapy study in triple breast cancer
TAILORx: a practice-changing breast cancer trial
ASCO18: Early-stage breast cancer patients could be spared chemotherapy, TAILORx trial shows
Genetic test may lead to more effective chemotherapy for triple-negative breast cancer
News round-up: 11th European Breast Cancer Conference
Treasure trove of 110 genes linked to breast cancer discovered
Novel blood test could quickly predict breast cancer patient’s response to palbociclib
Preventing unnecessary breast cancer treatment: an interview with Jelle Wesseling
Olaparib becomes the first drug approved for BRCA breast cancer
Ductal carcinoma in situ: how should we treat it?
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Expert Panel
  • Journals
  • Permissions and content ownership policy
  • Press release policy
  • Whitelist emails

Contact

Contact Us

Office info

Oncology Central is powered by Taylor & Francis Group

Oncology Central, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Oncology Central